Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-avibactam in Neonates with Gram-Negative Infections
NCT04126031Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jan 2020
- Primary completion
- Dec 2022
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 8
01
Overview
Phase 2, open-label trial of ceftazidime + avibactam in Gram-negative bacterial infection, sponsored by Pfizer. Primary endpoints: Plasma Concentrations of Ceftazidime and Avibactam at 7 hours, Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) and 3 more. Started Jan 2020; status: terminated.
02
Drugs
ceftazidime + avibactam
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on NCT04126031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04126031.